Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01308619 · ClinicalTrials.gov registry record · Phase 4

Evaluation of Rosacea-related Inflammatory Biochemical Markers in Adult Skin When Treated With Oracea® vs Placebo

A Phase 4 study, sponsored by Galderma R&D.

Completed
Registry status
Phase 4
Development phase
170
Enrollment target

NCT01308619: Completed Phase 4 study, sponsored by Galderma R&D.

NCT01308619 is a Phase 4 study that has completed, run by Galderma R&D. The registered enrollment target is 170 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (67% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01308619, a Phase 4 study, has completed, sponsored by Galderma R&D.

COMPLETED
Registry status
Phase 4
Development phase
170 participants
Enrollment target

Study Summary

The objective of this study is to determine the clinical effects of doxycycline 40 mg (30 mg immediate release and 10 mg delayed release beads) capsules (Oracea®) as compared to placebo in the skin of adults with papulopustular rosacea and to identify a correlation, if any, with rosacea-related inflammatory markers.

Primary Outcome

Mean change in inflammatory lesion counts from baseline to week 12

Interventions

  • OTHER Placebo
  • DRUG Doxycycline

Trial Details

FieldValue
Enrollment Target 170 participants
Start Date 2011-04
Est. Completion 2012-08
Phase Phase 4
Galderma R&D

158 total trials

What the finished NCT01308619 record still lists

NCT01308619 is an interventional study that assigns participants to a tested intervention. The registered 170 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (67% lower).

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT01308619 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01308619 about?

NCT01308619 is a clinical study titled "Evaluation of Rosacea-related Inflammatory Biochemical Markers in Adult Skin When Treated With Oracea® vs Placebo". The objective of this study is to determine the clinical effects of doxycycline 40 mg (30 mg immediate release and 10 mg delayed release beads) capsules (Oracea®) as compared to placebo in the skin of adults with papulopustular rosacea and to identify a correlation, if any, with rosacea-related infl...

What is the current status of trial NCT01308619?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 170 participants. The study started on 2011-04. Estimated completion is 2012-08.

What interventions are being tested in trial NCT01308619?

The interventions under investigation include: Placebo (OTHER), Doxycycline (DRUG).

Who is sponsoring clinical trial NCT01308619?

This trial is sponsored by Galderma R&D, which has 158 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01308619's enrollment target sits among peer trials

170 484th of 2000 higher than 1,514 of 2,000 other Phase 4 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02016430 · 170 participants · NA

    Gut Flora Metabolite Reduction After Dietary Intervention (GRADY)

  • NCT02621021 · 170 participants · Phase 2

    A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab

  • NCT04094701 · 170 participants · NA

    Hip Arthroscopy Postoperative Opioid Demands

  • NCT04166409 · 170 participants · Phase 3

    A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01308619, the US trial registry maintained by the National Library of Medicine. NCT01308619 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.